BARRX signs Japan distribution deal for ablation system
This article was originally published in Clinica
Executive Summary
BARRX Medical is to take its HALO radiofrequency ablation system to the Japanese market after signing an exclusive distribution deal with medical product supply company Medico’s Hirata. The HALO system, which is also FDA-cleared and CE-marked, is designed to treat gastroenterological diseases by removing diseased tissue and allowing the re-growth of new, normal cells. According to Sunnyvale, California-based BARRX, the HALO system “has shown encouraging results in recent clinical trials…in eradicating early oesophageal squamous neoplasia, a precursor to oesophageal cancer”. BARRX said that Japan has one of the highest concentrations of oesophageal squamous cell cancers in the world. Financial terms of the deal were not disclosed.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals